Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers
Targeting the renin-angiotensin-aldosterone system (RAAS), specifically the effector peptide angiotensin II (Ang II), represents a major opportunity for slowing the progression of cardiovascular disease (CVD) and, in turn, reducing the risk of morbidity and mortality. Inhibition of angiotensin-conve...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publications
2006-03-01
|
| Series: | Journal of the Renin-Angiotensin-Aldosterone System |
| Online Access: | http://jra.sagepub.com/content/7/1_suppl/1.full.pdf |